Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...
12d
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
Amgen and AstraZeneca have announced full results from the Phase III, registrational WAYPOINT trial showing that Tezspire ...
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
Clinical Trials Arena on MSN12d
Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...
Tezepelumab was first approved for treating ... were involved in the trial, named “Waypoint”, with 203 of those being given the active drug injections and the others being issued with a ...
10,11 WAYPOINT is a double-blind, multi-center, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP. 1,2,3 ...
March 01, 2025--(BUSINESS WIRE)--Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE ® (tezepelumab ... with nasal polyps (CRSwNP) compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback